Related references
Note: Only part of the references are listed.Mobitz type I and II atrioventricular blocks during fingolimod therapy
Francesco Sacca et al.
NEUROLOGICAL SCIENCES (2016)
The evolution of sex-specific virulence in infectious diseases
Francisco Ubeda et al.
NATURE COMMUNICATIONS (2016)
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study
Damiano Paolicelli et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Fingolimod and Risk of Varicella-Zoster Virus Infection Back to the Future With an Old Infection and a New Drug
Kenneth L. Tyler
JAMA NEUROLOGY (2015)
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod Risk Assessment and Consensus Recommendations for Management
Ann M. Arvin et al.
JAMA NEUROLOGY (2015)
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
Alice Laroni et al.
BMC NEUROLOGY (2014)
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
G. Francis et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
Ludwig Kappos et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
CONTINUING FINGOLIMOD AFTER DEVELOPMENT OF MACULAR EDEMA: A CASE REPORT
Vivien Li et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2014)
Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients
Andrew J. Fine et al.
CLINICAL INFECTIOUS DISEASES (2013)
T-cell response against varicella-zoster virus in fingolimod-treated MS patients
Meret E. Ricklin et al.
NEUROLOGY (2013)
Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases
Sabra L. Klein
BIOESSAYS (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Regulation of Mammalian Physiology, Development, and Disease by the Sphingosine 1-Phosphate and Lysophosphatidic Acid Receptors
Victoria A. Blaho et al.
CHEMICAL REVIEWS (2011)
CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis
Yi Jin et al.
DRUG METABOLISM AND DISPOSITION (2011)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis
Kumlesh K. Dev et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Finding a way out: lymphocyte egress from lymphoid organs
Susan R. Schwab et al.
NATURE IMMUNOLOGY (2007)
Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
Volker Brinkmann
PHARMACOLOGY & THERAPEUTICS (2007)
Fingolimod (FTY720) in severe hepatic impairment: Pharmacokinetics and relationship to markers of liver function
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
FTY720 pharmacokinetics in mild to moderate hepatic impairment
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients
K Budde et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats
A Kalsotra et al.
DRUG METABOLISM AND DISPOSITION (2002)
Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression
H Asanuma et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Share Paper
